MedTrace Logo

Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism

NCT07137364 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2025-08-22

No results posted yet for this study

Summary

The goal of this observational study is to learn about the optimal dose of spironolactone treatment and the long-term outcomes on cardiovascular and cerebrovascular events in patients with lateralized PA who are unwilling to undergo surgery. The main question it aims to answer is:

1. What is the long-term effect of spironolactone treatment for lateralized PA?
2. What is the optimal dose of spironolactone treatment for the relief of renin inhibition in patients with lateralized PA? Participants will receive spironolactone treatment as part of their regular medical care for more than 12 months, and their clinical indicators, including blood pressure, biochemical remission, cardiovascular and renal damage, and the incidence of cardiovascular and cerebrovascular events, will be analyzed.

Conditions

Interventions

DRUG

spironolactone

The patients receive spironolactone treatment based on their conditions

Sponsors & Collaborators

  • Third Military Medical University

    lead OTHER

Principal Investigators

  • Zhiming Zhu, MD · Department of Hypertension and Endocrinology, Daping Hospital, Army Medical University

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2025-12-01
Completion
2026-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07137364 on ClinicalTrials.gov